Các đột biến splicing có liên quan đến phản ứng lâm sàng trong nghiên cứu pha 1b/2 về chất ức chế PLK1 onvansertib kết hợp với decitabine ở bệnh nhân bạch cầu cấp myeloid tái phát hoặc kháng trị

Shallis RM, Zeidan AM, Wang R, Podoltsev NA (2021) Epidemiology of the Philadelphia chromosome-negative classical myeloproliferative neoplasms. Hematol Oncol Clin North Am 35(2):177–189 Jiang Y, Dunbar A, Gondek LP, Mohan S, Rataul M, O’Keefe C et al (2009) Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113(6):1315–1325 Chen J, Odenike O, Rowley JD (2010) Leukaemogenesis: more than mutant genes. Nat Rev Cancer 10(1):23–36 Wang ES (2014) Treating acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program 2014(1):14–20. https://doi.org/10.1182/asheducation-2014.1.14 DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7–17 Brancati S, Gozzo L, Romano GL, Vetro C, Dulcamare I, Maugeri C et al (2021) Venetoclax in relapsed/refractory acute myeloid leukemia: are supporting evidences enough? Cancers 14(1):22 Bewersdorf JP, Giri S, Wang R, Williams RT, Tallman MS, Zeidan AM et al (2020) Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica 105(11):2659–2663 Iliaki S, Beyaert R, Afonina IS (2021) Polo-like kinase 1 (PLK1) signaling in cancer and beyond. Biochem Pharmacol 193:114747. https://doi.org/10.1016/j.bcp.2021.114747 Barr Francis A, Silljé Herman HW, Nigg Erich A (2004) Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5(6):429–441 Degenhardt Y, Lampkin T (2010) Targeting Polo-like Kinase in cancer therapy. Clin Cancer Res 16(2):384–389 Goroshchuk O, Kolosenko I, Vidarsdottir L, Azimi A, Palm-Apergi C (2019) Polo-like kinases and acute leukemia. Oncogene 38(1):1–16 Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D et al (2012) NMS-P937, an orally available, specific small-molecule Polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther 11(4):1006–1016 Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S et al (2013) The Polo-like kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia. PLoS One 8(3):E58424 Zeidan AM, Ridinger M, Lin TL, Becker PS, Schiller GJ, Patel PA et al (2020) A phase Ib study of onvansertib, a novel oral PLK1 inhibitor, in combination therapy for patients with relapsed or refractory acute myeloid leukemia. Clin Cancer Res 26(23):6132–6140 Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21(24):4642–4649 Frankish A, Diekhans M, Ferreira A-M, Johnson R, Jungreis I, Loveland J et al (2019) GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res 47(D1):D766–D773 Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C (2017) Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods 14(4):417–419 Soneson C, Love MI, Robinson MD (2015) Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4:1521 Anders S, Huber W (2010) Differential expression analysis for sequence count data. Genome Biol 11(10):R106 Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550. https://doi.org/10.1186/s13059-014-0550-8 Christopoulos DT (2016) Introducing Unit Invariant Knee (UIK) as an objective choice for elbow point in multivariate data analysis techniques. Econometrics: Econometric & Statistical Methods - Special Topics eJournal, pp 7. https://doi.org/10.2139/ssrn.3043076 Hänzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 14(1):7. https://doi.org/10.1186/1471-2105-14-7 Smyth G (2005) Limma: linear models for microarray data. In: Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S (eds) Bioinformatics and computational biology solution using R and bioconductor. Statistics for Biology and Health, Springer, New York, pp 397–420. https://doi.org/10.1007/0-387-29362-0_23 Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W et al (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):E47 Xiao Y, Hsiao T-H, Suresh U, Chen H-IH, Wu X, Wolf SE et al (2014) A novel significance score for gene selection and ranking. Bioinformatics 30(6):801–807. https://doi.org/10.1093/bioinformatics/btr671 Epub 2012 Feb 9 Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545–15550 Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP (2011) Molecular signatures database (MSigDB) 3.0. Bioinformatics 27(12):1739–1740 Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B Methodol 57(1):289–300 Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL et al (2018) Functional genomic landscape of acute myeloid leukaemia. Nature 562(7728):526–531 Chen T (2016) XGBoost: a scalable tree boosting system. In: Proceedings of the 22nd ACM SIGKDD International Conference on Knowledge Discovery and Data Mining, vol 2016. ACM, New York, NY, USA, pp 785–794 Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447 Bohl SR, Dolnik A, Jensen T, Lang KM, Hackanson B, Gaidzik VI et al (2017) Gene expression analysis of decitabine treated AML: high impact of tumor suppressor gene expression changes. Leuk Lymphoma 58(9):2264–2267 Gao J, Chen Y-H, Peterson LC (2015) GATA family transcriptional factors: emerging suspects in hematologic disorders. Exp Hematol Oncol 4:28. https://doi.org/10.1186/s40164-015-0024-z Pollyea D, Stevens B, Jones C, Winters A, Pei S, Minhajuddin M et al (2018) Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med 24(12):1859–1866. https://doi.org/10.1038/s41591-018-0233-1 Poulain L, Sujobert P, Zylbersztejn F, Barreau S, Stuani L, Lambert M et al (2017) High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells. Leukemia 31(11):2326–2335 You R, Hou D, Wang B, Liu J, Wang X, Xiao Q et al (2022) Bone marrow microenvironment drives AML cell OXPHOS addiction and AMPK inhibition to resist chemotherapy. J Leukoc Biol 112(2):299–311 Ma X, Wang L, Huang D, Li Y, Yang D, Li T et al (2017) Polo-like kinase 1 coordinates biosynthesis during cell cycle progression by directly activating pentose phosphate pathway. Nat Commun 8(1):1506 Ochi Y, Ogawa S (2021) Chromatin-spliceosome mutations in acute myeloid leukemia. Cancers 13(6):1232. https://doi.org/10.3390/cancers13061232 Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T et al (2021) Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv 5(8):2173–2183 Caprioli C, Lussana F, Salmoiraghi S, Cavagna R, Buklijas K, Elidi L et al (2020) Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. Haematologica 106(10):2578–2587 Kim E, Ilagan JO, Liang Y, Daubner GM, Lee SC-W, Ramakrishnan A et al (2015) SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell 27(5):617–630 Moore MJ, Wang Q, Kennedy CJ, Silver PA (2010) An alternative splicing network links cell-cycle control to apoptosis. Cell 142(4):625–636 Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS et al (2016) TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med 375(21):2023–2036 Stomper J, Lübbert M (2019) Can we predict responsiveness to hypomethylating agents in AML? Semin Hematol 56(2):118–124 Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M et al (2022) International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200–1228 Binder M, Carr RM, Lasho TL, Finke CM, Mangaonkar AA, Pin CL et al (2022) Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nat Commun 13:1434. https://doi.org/10.1038/s41467-022-29142-6